Literature DB >> 30190973

CA 19-9 in combination with abdominal CT scan for the diagnosis of mass-forming intrahepatic cholangiocarcinoma.

Nilubol Raunroadroong1,1, Hutcha Sriplung2,2, Nirush Lertprasertsuke3,3, Suwalee Pojchamarnwiputh4,4, Witthanee Na Chiangmai4,4, Worapon Sinsuwan1,1, Sumitra Thongprasert5,5.   

Abstract

AIM: Cholangiocarcinoma (CCA) is a common form of cancer in Thailand. The diagnosis of CCA by pathology is widely accepted. Unfortunately, tissue diagnosis of mass-forming intrahepatic cholangiocarcinoma is difficult to perform due to the risk of the procedure and accessibility. The aim of this study is to assess the diagnostic utility of CA19-9 in combination with CT scan for the diagnosis of mass-forming cholangiocarcinoma. MATERIALS &
METHODS: The medical records of patients with a diagnosis of CCA and hepatocellular carcinoma (HCC) during January 2005-December 2009 were reviewed. Only cases with pathology and CT scan reports from Maharaj Nakorn Chiang Mai Hospital were included. Demographic data, clinical manifestations and laboratory results, including CA19-9 and CT scans of the liver, were carefully examined in order to establish their diagnostic utility in mass-forming CCA without a pathological diagnosis.
RESULTS: A total of 79 CCA patients and 66 HCC patients were included in CA19-9 cut-off level analyses. A total of 31 CCA patients and 44 HCC patients were included in the CT scan evaluation and scored according to the Chiang Mai CT score for CCA. The specificity of a CA19-9 value of 500 U/ml for the diagnosis of CCA was 95.5% with a sensitivity of 50.6%, positive predictive value of 91.8% and likelihood ratio of positive (LR+) of 11.24. A CT score greater than 2 demonstrates a positive predictive value of more than 90% in diagnosis of CCA. The CA19-9 level of 140 U/ml in combination with a CT score of 2 demonstrated LR+ as high as 57.09. A CA19-9 level of 280 U/ml in combination with a CT score of 1 demonstrated LR+ of 58.4.
CONCLUSION: A CA19-9 level combined with the Chiang Mai CT score for CCA are good diagnostic tools for the diagnosis of mass-forming cholangiocarcinoma with high specificity, high positive predictive value and high likelihood ratio of positive.

Entities:  

Keywords:  CA19-9 level; CT scan; Chiang Mai CT score for CCA; cholangiocarcinoma

Year:  2014        PMID: 30190973      PMCID: PMC6095427          DOI: 10.2217/hep.14.19

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  6 in total

Review 1.  Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings.

Authors:  Jae Hoon Lim
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

Review 2.  Imaging of intrahepatic and hilar cholangiocarcinoma.

Authors:  B I Choi; J M Lee; J K Han
Journal:  Abdom Imaging       Date:  2004-06-08

Review 3.  Cholangiocarcinoma: pictorial essay of CT and cholangiographic findings.

Authors:  Joon Koo Han; Byung Ihn Choi; Ah Young Kim; Su Kyung An; Joon Woo Lee; Tae Kyung Kim; Sun-Whe Kim
Journal:  Radiographics       Date:  2002 Jan-Feb       Impact factor: 5.333

4.  Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.

Authors:  Satoshi Yamamoto; Shoji Kubo; Seikan Hai; Takahiro Uenishi; Takatsugu Yamamoto; Taichi Shuto; Shigekazu Takemura; Hiromu Tanaka; Osamu Yamazaki; Kazuhiro Hirohashi; Takashi Tanaka
Journal:  Cancer Sci       Date:  2004-07       Impact factor: 6.716

5.  Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis.

Authors:  J C Nichols; G J Gores; N F LaRusso; R H Wiesner; D M Nagorney; R E Ritts
Journal:  Mayo Clin Proc       Date:  1993-09       Impact factor: 7.616

6.  Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case-control study.

Authors:  Kirati Poomphakwaen; Supannee Promthet; Supot Kamsa-Ard; Patravoot Vatanasapt; Wisit Chaveepojnkamjorn; Jeeranun Klaewkla; Dusit Sujirarat; Natchaporn Pichainarong
Journal:  Asian Pac J Cancer Prev       Date:  2009 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.